Drugs / calcium folinic acid
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05872841 Background | Jun 2023 → Dec 2024 | hepatocellular carcinoma, portal vein thrombosis | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06041477 Background | Oct 2023 → Jul 2027 expected | chemotherapy-induced toxicity, hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | calcium folinic acid | “calcium folinic acid 400mg/m2” NCT05872841 ↗ |
| Route | Other | “Hepatic arterial infusion chemotherapy with (oxaliplatin 135mg/m2 over 3hrs, calcium folinic acid 400mg/m2 or levofolinic acid 200mg/ m2 over 1.5hrs, 5-FU 400mg/m2 over 2hrs,...” NCT06041477 ↗ |